{"id":"arm-a-iv-iron-epoietin-zeta","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Iron overload / hemochromatosis"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IV iron provides the essential substrate for hemoglobin synthesis, while epoetin zeta (a recombinant erythropoietin) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells. Together, they address both iron deficiency and inadequate erythropoietin signaling in anemic patients, particularly those undergoing cancer treatment.","oneSentence":"This combination therapy replenishes iron stores and stimulates red blood cell production to treat chemotherapy-induced anemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:25.307Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced anemia in cancer patients"}]},"trialDetails":[{"nctId":"NCT02213653","phase":"PHASE4","title":"Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency","status":"TERMINATED","sponsor":"Centre Francois Baclesse","startDate":"2013-04","conditions":"Solid Cancer Metastatic Disease, Lymphoid Disease","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ARM A : IV iron + epoietin zeta","genericName":"ARM A : IV iron + epoietin zeta","companyName":"Centre Francois Baclesse","companyId":"centre-francois-baclesse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy replenishes iron stores and stimulates red blood cell production to treat anemia. Used for Chemotherapy-induced anemia, Anemia in cancer patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}